Why Pharma Marketing Agency Strategy Translates and Doesn't Translate to Medtech

In my experience working with medtech founders and their pharma-adjacent counterparts, the marketing agency pharma decision is one of the most consistently misframed in life sciences marketing.

Founders hire an agency expecting campaign production, media buys, and creative execution. What they really need is a category-and-attention shop that engineers the market position underneath every downstream marketing motion.

Great companies don't wait for markets to form. They engineer them, and the marketing agency pharma founders should hire is the one that supports that engineering across the eighteen months before commercial adoption compounds.

Over 400+ episodes of State of MedTech, the pattern is consistent.

Teams that treat marketing as campaign production get campaigns. Companies that treat it as category engineering and attention direction get category leadership, category authority signal, and the market position that closes deals across long life-science sales cycles.

Takeaways

• The marketing agency pharma founders should hire is a category-and-attention shop, not a campaign production vendor. Chamath's framework is exact. The job is to direct attention through perception, meaning, and repetition.
• Category, messaging, narrative, and go-to-market alignment are the four pillars of pharma marketing category strategy. Miss any of them and the whole system stalls.
• The number one marketer and voice of a category becomes the default answer to the buyer's search. Everything else in pharma marketing is downstream of that positioning.
• Demand creation and demand capture have to run as a coordinated one-two punch. Pharma marketing that only captures existing demand leaves the compounding value on the table.
• Challenger pharma brands have to demonstrate a specific advantage over the market-dominant brand. Great companies don't wait for markets to form, and challenger brands don't wait for buyers to notice them either.

Why Category, Messaging, Narrative, and Go-to-Market Are the Four Pillars

I made this exact point in an episode about how market engineering helps medtech startups raise capital:

"Your category is defining the problem, naming the category. Messaging is your positioning, your differentiation, your proofs. Narrative comes down to thought leadership, your point of view market education. Then go-to-market, sales and marketing alignment. The first thing that usually breaks is messaging because it's downstream from the category."

Read that as the operating structure for a marketing agency pharma engagement.

Category is the top of the stack. Naming the specific problem the pharma or medtech company is solving, framing it inside a specific worldview, and defining the category shape underneath everything else.

Messaging is downstream. Positioning against the market leader, differentiation on specific proofs, and the exact language the sales team uses in every conversation.

Narrative sits underneath messaging: category authority, market education, and the point of view repeated across every channel. Go-to-market is the operational execution surface where category, messaging, and narrative converge into pipeline.

The teams that get pharma marketing category strategy right build all four layers with the same agency partner across the eighteen-month window.

The companies that split the layers across separate vendors produce internal inconsistency the market reads as noise. Every disconnect between layers dilutes the category signal and slows the compounding curve.

Why Chamath Says the Job Is to Direct Attention

Chamath made this point in an episode about attention as the operating system of AI, media, and markets:

"Your job is to direct attention, right? To decide what you want the market to notice and then essentially engineer the conditions under which they notice that. The model I keep coming back to quite often is in three parts, which is perception, meaning, and repetition."

That is the operating principle underneath every good marketing agency pharma engagement.

Perception is what the audience sees first. The specific framing of the category, the visual identity, and the initial thesis the agency introduces into the market. Meaning is what the audience takes away.

The specific worldview the founder is trying to make load-bearing inside the audience's own thinking. Repetition is the mechanism that turns perception plus meaning into durable market position.

Traditional pharma agencies produce perception through creative and media. The good ones add meaning through category framing. The rare ones drive repetition across the eighteen months required for the market position to compound.

Most stop at perception. Most engagements produce a creative campaign, a media plan, a few production cycles, and no durable market position.

The marketing agency pharma founders should be paying for is the rare one that runs perception plus meaning plus repetition as a coordinated attention system. That is what closes durable market position. Everything else produces impressions without compounding.

Why the Number One Marketer Becomes the Default Answer

This came up directly in an episode about why medtech marketers must focus more on the buyer:

"If you're the number one marketer and voice of the category and the problem then by default people come to you for that solution."

That is the ultimate outcome of pharma marketing category strategy done well.

Once a founder or company becomes the default voice of the category, inbound compounds. Executives searching for solutions default to that name. Physicians researching new therapies default to that framing.

Health systems evaluating options default to that positioning. The founder no longer has to convince anyone the category is real, because the category is already recognized under the founder's name.

That outcome is not a campaign result. It is a market engineering outcome across eighteen months of consistent perception, meaning, and repetition.

The marketing agency pharma founders should hire is one whose portfolio shows evidence of producing that outcome for other companies, not one whose portfolio shows evidence of producing campaign metrics without downstream market position.

That is the market-product fit test for agency selection at the pharma layer. Does the agency's actual work compound category authority, or does it produce campaign impressions? The gap between the two outcomes is the difference between a real category-and-attention shop and a traditional creative vendor.

Why Demand Creation and Demand Capture Have to Move Together

That gap is the subject of an episode about the 90M medtech sales blind spot no one talks about:

"It's the one-two punch of creating the demand and then being ready to capture it, right? It's almost like lobbing a baseball really high up in the air. You got to kind of jog over to where it's going to land and catch that."

That is the operating coordination underneath pharma marketing that really produces pipeline.

Demand creation is the category work, the category authority, the narrative repetition. Demand capture is the paid search, the retargeting, the sales enablement, and the field team enablement. Most pharma marketing engagements do one or the other. Good ones coordinate both.

The marketing agency pharma founders should hire runs demand creation and capture as a coordinated system. Category content produces search demand that paid channels then capture at higher intent.

Narrative repetition produces awareness that field teams then convert in specific accounts. Every demand-creation asset is designed with the capture pathway already engineered.

That coordination is what separates agencies that produce durable pharma marketing category strategy from agencies that produce one-off campaign spikes.

Spikes evaporate. Coordinated systems compound. The founders who understand this pick agency partners on the coordination criterion, not on the creative reel.

Why Challenger Pharma Brands Have to Prove a Specific Advantage

That's the exact case made in an episode about how a mini robot can take on medtech giants:

"We are an underdog challenging a market leader. Challenger brands have to show that they have something to offer which is better than the market dominant brand."

That is the operating truth for every challenger pharma brand.

The market-dominant brand has scale advantages the challenger can't match.

Distribution, physician relationships, and payer contracts compound in favor of the incumbent. The challenger's only path is a specific, defensible advantage the incumbent can't easily copy or absorb.

The marketing agency pharma founders hire has to know how to frame that advantage for the specific audience segments that will move first. Physicians who are early adopters, patients who are frustrated with existing options, payers who are looking for cost-of-care use.

Each audience segment reads the challenger claim differently, and the agency has to have the segmentation depth to reach each one on its own terms.

Generic challenger framing fails because the market-dominant brand can absorb the specific claim through defensive marketing at scale. Specific, defensible framing tuned to the audience segment that will move first is what breaks through.

FDA clearance is the starting line, not the finish line. Clinical validation ≠ commercial traction.

And the traction gap between clearance and commercial adoption is exactly where challenger positioning either compounds into market share or gets absorbed by the incumbent. The marketing agency pharma founders choose determines which of the two happens.

Why Perception, Meaning, and Repetition Compounds Only With Consistent Investment

Most marketing agency pharma engagements underinvest in repetition: the perception layer gets creative budget, and the meaning layer gets a positioning workshop. Repetition gets whatever budget is left over, which is usually not enough to produce the compounding effect the first two layers were engineered for.

That underinvestment is the failure mode Chamath's model surfaces.

Perception without repetition fades. Meaning without repetition never sticks. The compounding curve depends on all three layers running consistently across the full eighteen-month window.

The medtech leaders who get pharma marketing category strategy right budget the repetition layer up front. They calendar the sixty pieces of content per quarter that reinforce the perception and meaning frames.

They wire the internal enablement stack so every field conversation carries the same category signal. They pay the media budget that keeps the perception surface warm across every quarter.

That level of consistent investment is what separates agencies that produce durable category authority from agencies that produce a launch spike followed by nine months of silence. The companies that understand the compounding math budget accordingly.

They stop measuring the marketing agency pharma engagement against ninety-day campaign metrics. They start measuring against category signal at month twelve and eighteen.

They hold the agency to the cadence that produces the compounding, and they refuse to pull the budget mid-way just because the ninety-day metrics look softer than the paid-search benchmark.

That budget discipline is what most engagements never achieve. And it is why most pharma marketing agency contracts produce impressions without the category authority the founder was really paying for.

What This Means for Pharma and Medtech Founders

The marketing agency pharma founders should hire is a category-and-attention shop that engineers the market position underneath every downstream marketing motion.

It has to deliver category work, messaging, narrative, and go-to-market alignment as a coordinated system. It has to run perception, meaning, and repetition as an attention engineering discipline.

It has to coordinate demand creation and demand capture across the same cadence, and it has to know how to frame challenger positioning against market-dominant incumbents in a way the incumbent can't easily absorb.

Founders evaluating agencies against this five-part spec should ask to see evidence of each layer in a prior engagement, not just a creative portfolio. An agency that can only point to campaign case studies is optimized for the wrong outcome.

This is the same discipline behind why hiring a healthcare marketing agency before defining your category burns 12 months of medtech runway. Category has to come first. Every downstream marketing motion depends on the category work compounding underneath it.

That's how we approach it at MarketCraft with the medtech and pharma-adjacent founders we work with. The marketing agency pharma founders really need is a market engineering partner, not a campaign vendor. Medtech leaders who hire on that spec close deals, drive commercial adoption, and compound authority the operators who hire on the campaign spec never build.

Restructuring the Engagement From the First Conversation

The founders who understand this shift restructure their marketing agency pharma engagement from the first conversation.

They contract for category work, not creative production. They budget for eighteen months of repetition, not a ninety-day launch spike. They hold the agency to operating outcomes, not campaign metrics.

That restructuring is what produces the compounding curve every founder is really trying to reach, and it is the single most consequential decision most founders make in the first eighteen months of their marketing program.

Getting it right compounds. Getting it wrong burns a year of runway on a spec that was never engineered for the outcome the founder wanted in the first place.

The clearest pattern I've seen across the medtech and pharma founders on the show is that the ones who ended up with real category authority made this decision deliberately.

They interviewed multiple agencies, asked to see the specific category work each had produced, and rejected agencies whose portfolio showed campaign spikes without compounding market position.

Frequently Asked Questions

What Should Pharma Founders Look For in a Marketing Agency?

Category work, messaging, narrative, and go-to-market alignment delivered as a coordinated system. The right agency partner runs perception, meaning, and repetition as an attention engineering discipline. The wrong one produces campaign impressions and no durable market position.

How Does Pharma Marketing Category Strategy Differ From Traditional Campaign Work?

Category strategy engineers the market position underneath every downstream campaign. It defines the problem, names the category, and produces the market narrative other companies then have to respond to. Campaign work executes creative and media inside a category the founder is assumed to have already engineered.

What Is the Relationship Between Demand Creation and Demand Capture?

Demand creation is the category work, category authority, and narrative repetition. Demand capture is the paid search, retargeting, sales enablement, and field team execution. They have to move together.

Creation without capture produces awareness that never converts. Capture without creation converts at low intent because the founder never engineered the market to want the product in the first place.

How Should Challenger Pharma Brands Position Against Market Leaders?

With a specific, defensible advantage tuned to the audience segment that will move first. Generic challenger framing fails because the market-dominant brand can absorb the specific claim through defensive scale marketing. Specific, defensible framing tuned to the early-adopting audience segment is what breaks through and compounds market share.

Listen to the Full Conversations

• How Market Engineering Helps Medtech Startups Raise Capital
• Chamath Was Right: Attention Is the Operating System of AI, Media, and Markets
• Why Medtech Marketers Must Focus More on the Buyer
• The $90M Medtech Sales Blind Spot No One Talks About
• How This Mini Robot Can Take On Medtech Giants

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, a leading podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.